MedShape, Inc. recently launched a novel DynaNail Mini Fusion System for Subtalar Fusion cases which features a patented superelastic nickel titanium (NiTiNOL) technology.
Superelastic Nail for Subtalar Fusion Launched
2 min read Premium comments
Secondary#dynanailminifusionsystem#nitinoltechnology#subtalarfusion
The DynaNail Mini Fusion System is designed for subtalar fusion because it maintains active compression after the surgery to better facilitate healing and stability. It was featured at the American Orthopaedic Foot & Ankle Society annual meeting held September 12-15, 2019 in Chicago.
NiTiNOL technology has pseudoelastic properties that allows for dynamic compression that is needed to improve healing at the fusion site. While this technology is not necessarily new, it is a new application.
The DynaNail TTC Fusion System was first introduced in 2013 and it incorporates a NiTiNOL component inside an intramedullary nail. Geared toward high risk patients, the system has resulted in successful outcomes.
According to the press release, “The release of the DynaNail Mini signifies another milestone with the successful miniaturization of the internal NiTiNOL Element while still retaining the same dynamic compression performance, thus expanding the DynaNail brand to other applications.”
The DynaNail Mini is under a limited market release. Terrence Philbin, D.O. of Orthopedic Foot &Ankle in Columbus, Ohio, was one of the first surgeons to use the DynaNail Mini.
He said, “I was initially attracted to the DynaNail due to its excellent post-operative compression, particularly in patients with poor bone quality. From my experience so far, I have found the Mini nail to be easy to use and the results reproducible across my patient population.”
Naohiro Shibuya, DPM of Texas A&M College of Medicine has also used the DynaNail Mini and said, “There is finally an option to achieve compression in the foot other than staples. The DynaNail Mini nail allows long-term stability of the arthrodesis site without losing compression after bone resorption.”
“As a market leader in NiTiNOL devices, we are proud to provide another novel solution that surgeons can add to their arsenal of surgical tools to address challenging pathologies,” said Kurt Jacobus, MedShape’s CEO.
“The early successful outcomes observed with the DynaNail Mini further validate the expansion of the DynaNail technology to other foot and ankle and trauma fusion applications. We are excited to see what the future holds.”
MedShape, Inc. is a medical device company headquartered in Atlanta, Georgia.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.